Health
AstraZeneca’s biologic combo AZD7442 for COVID-19 moving ahead – The Pharma Letter
AstraZeneca’s biologic combo AZD7442 for COVID-19 moving ahead
British scientists are trialling a new drug that could prevent people who have been exposed to the novel…To continue reading The Pharma Letter please login, subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space.
Or, if you’re only interested in reading the content about a specific topic (M&A, coronavirus/COVID-19, pricing, reimbursement and access, outsourcing,…
-
General21 hours agoCoalition abandons ‘end’ to work from home, walks back 41,000 job cuts
-
Noosa News11 hours agoBanana farmers still salvaging fruit four weeks after ex-Tropical Cyclone Alfred
-
Business15 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?
-
Business11 hours ago1 ASX dividend stock down 43% I’d buy right now